Gene-Editing Firm Taps IPO Wave With Plans To Raise $100M
Gene-editing medicines developer Metagenomi Inc. on Monday unveiled a price range on an estimated $100 million initial public offering, represented by Goodwin Procter LLP and underwriters counsel Davis Polk & Wardwell...To view the full article, register now.
Already a subscriber? Click here to view full article